Form 4: Acrivon CDO Tax Withholding on RSU Vesting

Acrivon Therapeutics' Chief Development Officer, Erick Gamelin, had 403 shares withheld for tax obligations upon restricted stock unit vesting.

Summary

• Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on August 14, 2025.
• The transaction involved the disposition of 403 shares of Common Stock.
• These shares were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The shares were valued at $1.39 per share for the purpose of tax withholding.
• Following this transaction, Erick Gamelin directly beneficially owns 15,686 shares of Common Stock.

Sentiment

Score: 6

Explanation: The transaction is a routine tax withholding event following RSU vesting, which is a positive for the employee but neutral for the company's operational performance. It indicates compensation being realized.

Positives

• The transaction indicates the vesting of restricted stock units (RSUs), which is a positive event for the employee as it represents earned compensation.
• The withholding of shares for tax purposes is a standard and expected procedure for RSU vesting, ensuring compliance with tax obligations.

Negatives

• The disposition of shares, even for tax withholding, reduces the direct share count held by the officer.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries when restricted stock units vest. It does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation-related transaction, not a sale into the open market. It reflects a portion of executive compensation being realized.
• Employees: Positive for the reporting person (Erick Gamelin) as it signifies the vesting and realization of restricted stock units, a form of compensation.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding event related to the vesting of restricted stock units for an executive. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation-related disclosure.

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Erick Gamelin, Chief Development Officer, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Stock